Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 38Neoplasm Metastasis 16Leukemia, Myeloid, Acute 13Skin Neoplasms 10Kidney Neoplasms 10Leukemia 9Carcinoma, Renal Cell 9Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 6Lymphoma, Non-Hodgkin 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Congenital Abnormalities 4Neuroblastoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Recurrence 2Papillomavirus Infections 2Pancreatic Neoplasms 2Lymphoma, Mantle-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1

Interventions

Cisplatin 32human papillomavirus vaccine, L1 type 16, 18 16Brachytherapy 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Paclitaxel 11Bevacizumab 11pembrolizumab 10Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Topotecan 8Radiotherapy, Intensity-Modulated 8Radiation 8Papillomavirus Vaccines 8atezolizumab 6Gemcitabine 6Fluorodeoxyglucose F18 6Cyclophosphamide 6tisotumab vedotin 5fludarabine phosphate 5fludarabine 5aldesleukin 5Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Carboplatin 5Vaccines, Synthetic 4Nivolumab 4Immunoglobulin G 4Disulfides 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Uterine Cervical Neoplasms × Interleukin-2 × Clear all
NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02280811 2017-09-06

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
12 enrolled 19 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡